Literature DB >> 12698050

Surgical management of patients with combined glaucoma and corneal transplant surgery.

Richard K Lee1, Francisco Fantes.   

Abstract

The reasons for having combined glaucoma and corneal transplant surgery are myriad. Patients with corneal transplants have a high frequency of developing secondary glaucoma. Patients with preexisting glaucoma have even higher risk for developing glaucoma refractory to medical management after penetrating keratoplasty. The indication for corneal transplant affects the risk for developing postkeratoplasty glaucoma. The surgical treatment options for treating glaucoma include laser trabeculoplasty, cycloablation, trabeculectomy, and glaucoma drainage implants. In addition, the sequencing of glaucoma surgery relative to penetrating keratoplasty affects the outcome. Newer corneal transplant techniques may have a lower risk for developing secondary glaucoma.

Entities:  

Mesh:

Year:  2003        PMID: 12698050     DOI: 10.1097/00055735-200304000-00008

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  4 in total

1.  Optical coherence tomography of the anterior segment in secondary glaucoma with corneal opacity after penetrating keratoplasty.

Authors:  Farnaz Memarzadeh; Yan Li; Brian A Francis; Ronald E Smith; Julie Gutmark; David Huang
Journal:  Br J Ophthalmol       Date:  2006-09-14       Impact factor: 4.638

2.  Glaucoma Drainage Devices and Reasons For Keratoplasty.

Authors:  Catherine G Knier; Feng Wang; Keith Baratz; Cheryl L Khanna
Journal:  J Glaucoma       Date:  2019-10       Impact factor: 2.503

Review 3.  The management of complicated glaucoma.

Authors:  C I Clement; Ivan Goldberg
Journal:  Indian J Ophthalmol       Date:  2011-01       Impact factor: 1.848

4.  Graft Survival after Penetrating Keratoplasty in Cases of Trabeculectomy versus Ahmed Valve Implant.

Authors:  Abdelhamid Elhofi; Hany Ahmed Helaly
Journal:  J Ophthalmol       Date:  2018-08-13       Impact factor: 1.909

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.